Previous 10 | Next 10 |
Shares of cancer diagnostics concern Veracyte, Inc. have shot up approximately 60% over the past month, snapping a deep decline. That said, valuations were stratospheric (22.6x FY21 sales at their peak), but shares of unprofitable Veracyte now trade at just under seven times FY22E sal...
Myriad Genetics' ( NASDAQ: MYGN ) GeneSight Psychotropic test led to significant improvements in depression remission rates, according to a new study . The test can help determine how an individual may metabolize or respond to certain psychiatric medications. This...
SALT LAKE CITY, July 12, 2022 (GLOBE NEWSWIRE) -- Major Depressive Disorder (MDD) remission rates were significantly improved when clinicians had access to GeneSight ® Psychotropic test results from Myriad Genetics, Inc. (NASDAQ: MYGN), according to a new nationwide...
2021 report demonstrates focus on ESG initiatives supporting health equity, social justice, and sustainability SALT LAKE CITY, June 28, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today released its first ...
Myriad Genetics (NASDAQ:MYGN) said it was teaming up with healthcare software firm Epic to integrate its full line of genetic tests with Epic’s physicians and more than 250M patients. The integration will allow healthcare providers to order Myriad tests and review results directly...
Healthcare providers can easily order Myriad’s genetic tests for the more than 250 million patients within Epic’s network Partnership bolsters Myriad’s growth plan to scale customer-centric, tech-enabled commercial capabilities with over 600 EHR integrations t...
Illumina (NASDAQ:ILMN) announced on Wednesday the launch of TruSight Oncology 500, a next-generation sequencing (NGS)–based assay jointly-developed with Merck (MRK) to unlock insights about the tumor genome. TruSight Oncology 500 is designed to identify genetic mutations used in the ev...
SALT LAKE CITY, June 09, 2022 (GLOBE NEWSWIRE) -- Paul J. Diaz, president and CEO of Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will discuss the company’s transformation and growth plan during a fireside chat at the Goldman Sachs 4...
Glenview Capital Management’s 13F portfolio value increased from $4.69B to $4.94B this quarter. The number of positions increased from 57 to 60. They increased Cigna, DXC Technology, Fiserv, US Foods Holding, Amazon.com, and Aptiv plc while decreasing McKesson, Bausch Health, F...
SALT LAKE CITY, May 26, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will present multiple studies at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, highlighting the value of genetic insights t...
News, Short Squeeze, Breakout and More Instantly...
2024-04-23 07:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
SALT LAKE CITY, April 17, 2024 (GLOBE NEWSWIRE) -- An astonishing 44% of Americans feel they have lost time in their lives due to poor mental health. That number jumps to nearly 80% for those diagnosed with anxiety and/or depression, according to the latest GeneSight Mental Health Monitor, a ...
SALT LAKE CITY, April 16, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that Prenatal Diagnosis has published a study 1 demonstrating exceptional positive predictive value (PPV) for 22q11.2 micr...